


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (original): A compound of the formula



wherein

R₁ is -CH₂-X, -O-X or -S(O)₀₋₂-X; or

R₁ is -NR₈-X, -NR₈C(O)-X or -NR₈S(O)₂-X in which

R₈ is hydrogen or lower alkyl; and

X is -(CH₂)_m-(CR₉R₁₀)_p-(CH₂)_n-Z-(CH₂)_q-W in which

m, n and q are independently zero or an integer from 1 to 5;

p is zero or 1;

R₉ and R₁₀ are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or

R₉ and R₁₀ combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

Z is a bond; or

Z is O, S(O)₀₋₂, or -NR₁₁- in which

R₁₁ is hydrogen or lower alkyl, provided that R₁ is -CH₂-X when m, n and p are all zero;

W is aryl or heterocyclyl;

R₂ is hydrogen, halogen, cyano, hydroxy or lower alkoxy;

L is a bond; or

L is -(CH₂)_s-O-(CH₂)_v- in which

s and v are independently zero or an integer from 1 to 3; or

L is $-C(O)-$, $-C(O)O-$, $-OC(O)-$, $-OC(O)NR_{12}-$, $-NR_{12}-$, $-NR_{13}C(O)-$, $-NR_{13}C(O)O-$ or $-NR_{13}C(O)NR_{12}-$ in which

R_{12} and R_{13} are independently hydrogen or lower alkyl;

R_3 is hydrogen, hydroxy, halogen or cyano provided that L is a bond; or

R_3 is optionally substituted lower alkyl, aralkyl, heteroaralkyl, aryl or heterocyclyl; or

R_3 and R_{12} combined are alkylene which together with the nitrogen atom to which they are attached form a 5- to 6-membered ring;

R_4 is hydrogen, optionally substituted lower alkyl or aryl;

R_5 and R_6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

R_5 and R_6 combined together with the carbon atoms to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided that R_5 and R_6 are attached to carbon atoms adjacent to each other; or

R_5 and R_6 combined are alkylene which together with the carbon atoms to which they are attached form a fused 5- to 7-membered ring provided that R_5 and R_6 are attached to carbon atoms adjacent to each other; or

C- R_5 and C- R_6 may be replaced with nitrogen;

R_7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy, cycloalkyl, alkanoyl, alkyloxyalkoxy, alkanoyloxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, carboxy, alkoxy carbonyl, aryl, alkenyl, alkynyl, aralkoxy, heterocyclyl including indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl, piperidyl, morpholinyl and tetrazolyl; or

R_7 and R_6 combined are O, $S(O)_{0-2}$, $-NR_{14}-$, $-(CH_2)_{1-2}-$, $-O-CH_2-$, $-CH_2-O-$, $-S(O)_{0-2}-CH_2-$, $-CH_2-S(O)_{0-2}-$, $-NR_{14}-CH_2-$, $-CH_2-NR_{14}-$, $-S(O)_{0-2}-NR_{14}-$ or $-NR_{14}-S(O)_{0-2}-$ in which

R_{14} is hydrogen or lower alkyl, provided R_6 is located at the 2' position; or

C- R_7 may be replaced with nitrogen;

Y is $-(CH_2)_r-$, $-O-(CH_2)_r-$, $-(CH_2)_r-O-$, $-S_{0-2}-(CH_2)_r-$ or $-(CH_2)_r-S_{0-2}-$ in which

r is zero or an integer from 1 to 3;

Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or

Q combined with the atoms to which it is attached form a 7- to 12-membered bicyclic aromatic or heterocyclic ring;
or a pharmaceutically acceptable salt thereof.

Claim 2 (original): A compound according to Claim 1 wherein

R_1 is $-\text{CH}_2\text{-X}$, $-\text{O-X}$ or $-\text{S(O)}_{0-2}\text{-X}$; or

R_1 is $-\text{NR}_8\text{-X}$, $-\text{NR}_8\text{C(O)-X}$ or $-\text{NR}_8\text{S(O)}_2\text{-X}$ in which

R_8 is hydrogen or lower alkyl; and

X is $-(\text{CH}_2)_m\text{-(CR}_9\text{R}_{10})_p\text{-(CH}_2)_n\text{-Z-(CH}_2)_q\text{-W}$ in which

m and n are independently zero or an integer from 1 to 5;

p is zero or 1;

q is zero;

R_9 and R_{10} are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or

R_9 and R_{10} combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

Z is a bond; or

Z is O, S(O)_{0-2} , or $-\text{NR}_{11}-$ in which

R_{11} is hydrogen or lower alkyl, provided that R_1 is $-\text{CH}_2\text{-X}$ when m, n and p are all zero;

W is aryl or heterocyclyl;

R_2 is hydrogen, halogen, cyano, hydroxy or lower alkoxy;

L is a bond; or

L is $-(\text{CH}_2)_s\text{-O-(CH}_2)_v\text{-}$ in which

s and v are zero; or

L is $-\text{C(O)-}$, $-\text{C(O)O-}$, $-\text{OC(O)-}$, $-\text{OC(O)NR}_{12}\text{-}$, $-\text{NR}_{12}\text{-}$, $-\text{NR}_{13}\text{C(O)-}$, $-\text{NR}_{13}\text{C(O)O-}$ or $-\text{NR}_{13}\text{C(O)NR}_{12}\text{-}$ in which


R_{12} and R_{13} are independently hydrogen or lower alkyl;

R_3 is hydrogen, halogen or cyano provided that L is a bond; or

R_3 is optionally substituted lower alkyl, aralkyl, heteroaralkyl, aryl or heterocyclyl; or

R_3 and R_{12} combined are alkylene which together with the nitrogen atom to which they are attached form a 5- to 6-membered ring;

R_4 is hydrogen, optionally substituted lower alkyl or aryl;



wherein

R_1 , R_2 , L , R_3 , R_4 , R_5 , R_6 , R_7 and Q have meanings as defined in Claim 2;

or a pharmaceutically acceptable salt thereof.

Claim 5 (original): A compound according to Claim 4 wherein

R_1 is $-\text{CH}_2\text{-X}$, $-\text{O-X}$ or $-\text{S-X}$; or

R_1 is $-\text{NR}_8\text{-X}$, $-\text{NR}_8\text{C(O)-X}$ or $-\text{NR}_8\text{S(O)}_2\text{-X}$ in which

R_8 is hydrogen or lower alkyl; and

X is $-(\text{CH}_2)_m\text{-(CR}_9\text{R}_{10})_p\text{-(CH}_2)_n\text{-Z-W}$ in which

m and n are independently zero or an integer of 1 or 2;

p is zero or 1;

R_9 and R_{10} are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or

R_9 and R_{10} combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

Z is a bond; or

Z is O , S(O)_{0-2} , or $-\text{NR}_{11}-$ in which

R_{11} is hydrogen or lower alkyl, provided that R_1 is $-\text{CH}_2\text{-X}$ when m , n and p are all zero;

W is aryl or heterocyclyl;

R_2 is hydrogen, halogen or hydroxy;

L is a bond;

R_3 is hydrogen or halogen;

R_4 is hydrogen, optionally substituted lower alkyl or aryl;

R_5 and R_6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

R₇ is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

R₇ and R₆ combined are O, S(O)₀₋₂, -NR₁₄-, -(CH₂)₁₋₂-, -O-CH₂-, -CH₂-O-, -S(O)₀₋₂-CH₂-, -CH₂-S(O)₀₋₂-, -NR₁₄-CH₂-, -CH₂-NR₁₄-, -S(O)₀₋₂-NR₁₄- or -NR₁₄-S(O)₀₋₂- in which

R₁₄ is hydrogen or lower alkyl, provided R₆ is located at the 2'-position;

Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or

Q combined with the atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

Claim 6 (original): A compound according to Claim 5 wherein

R₁ is -CH₂-X, -O-X or -S-X; or

R₁ is -NR₈-X, -NR₈C(O)-X or -NR₈S(O)₂-X in which

R₈ is hydrogen or lower alkyl; and

X is -(CH₂)_m-(CR₉R₁₀)_p-(CH₂)_n-Z-W in which

m and n are independently zero or an integer of 1 or 2;

p is zero or 1;

R₉ and R₁₀ are independently hydrogen or lower alkyl; or

Z is a bond; or

Z is O, S(O)₀₋₂, or -NR₁₁- in which

R₁₁ is hydrogen or lower alkyl, provided that R₁ is -CH₂-X when m, n and p are all zero;

W is aryl or heterocyclyl;

R₂ is hydrogen, halogen or hydroxy;

L is a bond;

R₃ is hydrogen or halogen;

R₄ is hydrogen;

R₅ and R₆ are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

R₇ is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

R_7 and R_6 combined are O, $S(O)_{0-2}$, $-NR_{14}-$, $-(CH_2)_{1-2}-$, $-O-CH_2-$, $-CH_2-O-$, $-S(O)_{0-2}-CH_2-$, $-CH_2-S(O)_{0-2}-$, $-NR_{14}-CH_2-$, $-CH_2-NR_{14}-$, $-S(O)_{0-2}-NR_{14}-$ or $-NR_{14}-S(O)_{0-2}-$ in which

R_{14} is hydrogen or lower alkyl, provided R_6 is located at the 2'-position;

Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or

Q combined with the atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

Claim 7 (original): A compound according to Claim 6 wherein

R_1 is $-NR_8-X$, $-NR_8C(O)-X$ or $-NR_8S(O)_2-X$ in which

R_8 is hydrogen or lower alkyl;

or a pharmaceutically acceptable salt thereof.

Claim 8 (original): A compound according to Claim 6 wherein


Q combined with the carbon atoms to which it is attached form a pyridyl or pyrimidinyl ring;
or a pharmaceutically acceptable salt thereof.

Claim 9 (original): A compound according to Claim 6 wherein

Q combined with the carbon atoms to which it is attached form a thienyl, furyl, pyrrolyl or indolyl ring;

or a pharmaceutically acceptable salt thereof.

Claim 10 (original): A compound according to Claim 5 of the formula



wherein

R_1 is $-CH_2-X$, $-O-X$ or $-S-X$; or

R_1 is $-NR_8-X$, $-NR_8C(O)-X$ or $-NR_8S(O)_2-X$ in which

R_8 is hydrogen or lower alkyl; and

X is $-(CH_2)_m-(CR_9R_{10})_p-(CH_2)_n-Z-W$ in which

m, n and p are independently zero or 1;

R_9 is hydrogen;

R_{10} is hydrogen or lower alkyl;

Z is a bond; or

Z is O, $S(O)_{0-2}$, or $-NR_{11}-$ in which

R_{11} is hydrogen or lower alkyl, provided that R_1 is $-CH_2-X$ when m, n and p are all zero;

W is aryl or heterocyclyl;

R_2 is hydrogen;

R_3 is hydrogen or halogen;

R_5 and R_6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

R_7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

R_7 and R_6 combined are O, $S(O)_{0-2}$, $-NR_{14}-$, $-(CH_2)_{1-2}-$, $-O-CH_2-$, $-CH_2-O-$, $-S(O)_{0-2}-CH_2-$, $-CH_2-S(O)_{0-2}-$, $-NR_{14}-CH_2-$, $-CH_2-NR_{14}-$, $-S(O)_{0-2}-NR_{14}-$ or $-NR_{14}-S(O)_{0-2}-$ in which

R_{14} is hydrogen or lower alkyl, provided R_6 is located at the 2'-position;

R_{15} is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 11 (original): A compound according to Claim 10 wherein

R_1 is $-O-X$ or $-S-X$; and

X is $-(CH_2)_m-(CR_9R_{10})_p-(CH_2)_n-Z-W$ in which

m is 1;

n and p are zero;

Z is a bond;

W is aryl or heterocyclyl;

R_3 is hydrogen or halogen;

R_5 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

R₆ is hydrogen;

R₇ is hydrogen;

R₁₅ is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 12 (original): A compound according to Claim 11 wherein

R₃ is hydrogen;

or a pharmaceutically acceptable salt thereof.

Claim 13 (original): A compound according to Claim 12 wherein

W is monocyclic aryl;

or a pharmaceutically acceptable salt thereof.


Claim 14 (original): A compound according to Claim 5 wherein

p is 1;

R₉ and R₁₀ combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;

or a pharmaceutically acceptable salt thereof.

Claim 15 (original): A compound according to Claim 14 of the formula



wherein

R₁ is -CH₂-X, -O-X or -S-X; or

R₁ is -NR₈-X, -NR₈C(O)-X or -NR₈S(O)₂-X in which

R₈ is hydrogen or lower alkyl; and

X is -(CH₂)_m-CR₉R₁₀-(CH₂)_n-Z-W in which

m and n are 1;

Z is a bond; or

Z is O, S(O)₀₋₂, or -NR₁₁- in which

R₁₁ is hydrogen or lower alkyl, provided that R₁ is -CH₂-X when m, n and p are all zero;

W is aryl or heterocyclyl;

R₂ is hydrogen;

R₃ is hydrogen or halogen;

R₅ and R₆ are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

R₇ is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or

R₇ and R₆ combined are O, S(O)₀₋₂, -NR₁₄-, -(CH₂)₁₋₂-, -O-CH₂-, -CH₂-O-, -S(O)₀₋₂-CH₂-, -CH₂-S(O)₀₋₂-, -NR₁₄-CH₂-, -CH₂-NR₁₄-, -S(O)₀₋₂-NR₁₄- or -NR₁₄-S(O)₀₋₂- in which

R₁₄ is hydrogen or lower alkyl, provided R₆ is located at the 2'-position;

R₁₅ is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 16 (original): A compound of claim 15 wherein

R₁ is -O-X or -S-X; and

X is -CH₂-CR₉R₁₀-CH₂-Z-W in which

Z is a bond;

W is aryl;

R₃ is hydrogen;

R₅ is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

R₆ is hydrogen;

R₇ is hydrogen;

R₁₅ is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;

or a pharmaceutically acceptable salt thereof.

Claim 17 (original): A method for the inhibition of renin activity in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

Claim 18 (original): A method for the prevention and/or treatment of conditions associated with renin activity in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

Claim 19 (original): A method according to Claim 18, which method comprises administering said compound in combination with a therapeutically effective amount of an anti-diabetic agent, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.

Claim 20 (original): A method for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

Claim 21 (original): A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with one or more pharmaceutically acceptable carriers.

Claim 22 (original): A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a therapeutically effective amount of an anti-diabetic agents, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.

Claim 23 (cancelled):

Claim 24 (cancelled):

Claim 25 (cancelled).

Claim 26 (cancelled):

Claim 27 (cancelled):

Claim 28 (cancelled):